Healthcare Global Enterprises Limited has informed the Exchange that the Competition Authority of Kenya vide its letter dated 7 May 2025 has approved the sale of upto 54% of voting share capital of the Company by Aceso Company Pte. Ltd to Hector Asia Holdings II Pte. Ltd. and KIA EBT II Scheme 1.
HCG · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.3 pts less than Nifty Microcap 250 and 0.5 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Healthcare Global Enterprises Limited (HCG) has received approval from the Competition Authority of Kenya (CAK) for the proposed sale of up to 54% of the company's voting share capital. The shares are being sold by Aceso Company Pte. Ltd to Hector Asia Holdings II Pte. Ltd. and KIA EBT II Scheme 1. This is a key regulatory milestone following the Competition Commission of India's (CCI) approval on 2 May 2025 and the original share purchase agreement signed on 23 February 2025. The deal still requires other regulatory clearances before it can be completed. HCG is a listed company on NSE and BSE, and this transaction represents a change in controlling shareholder.
This regulatory approval brings the deal closer to completion, which would result in a change of control at HCG. Shareholders should expect further updates on remaining regulatory clearances and any consequent open offer obligations under SEBI takeover rules.